- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07877727
Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network (2023-12377081)
Potenziare la Gestione Clinica Delle CMF Attraverso Una Rete Nazionale Pediatrica e Dell'Adulto Basata su Dati Biologici e Genetici / Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network
A non-profit, translational, prospective and retrospective study.
Patients will be enrolled according to the procedures described in the protocol, and samples will be processed and analyzed as specified in the protocol.
Since constitutional bone marrow failure syndromes (CMF) are rare genetic disorders characterized by a variable and incompletely defined clinical phenotype, a partially unknown genetic etiology, and pathogenetic mechanisms that are only partly understood, the investigators hypothesize that a number of patients currently diagnosed with idiopathic acquired aplastic anemia (AAA) or idiopathic single-lineage/multilineage bone marrow failure (BMF) may have been misdiagnosed and may actually have an underlying CMF.
Therefore, the investigators' primary objective is to identify CMF underlying BMF and vice versa, by defining well-characterized patient cohorts based on clinical and family history, clinical manifestations, and immunological findings; identifying disease-specific parameters and biomarkers; and providing disease-specific guidelines to facilitate early diagnosis and, consequently, enable timely and appropriate treatment.
In this context, the use of appropriate artificial intelligence (AI) tools is likely to improve the diagnostic accuracy of this approach.
Studieoversigt
Status
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Carlo Dufour
- Telefonnummer: +3901056363528
- E-mail: segrematologia@gaslini.org
Studiesteder
-
-
-
Avellino, Italien
- Rekruttering
- AORN San Giuseppe Moscati Hematology and bone marrow Transplant Unit
-
Kontakt:
- Antonio Maria Risitano
- Telefonnummer: +393475786759
- E-mail: amrisita@unina.it
-
Genova, Italien
- Rekruttering
- IRCCS Istituto Giannina Gaslini
-
Kontakt:
- Carlo Dufour
- Telefonnummer: +3901056363528
- E-mail: segrematologia@gaslini.org
-
Naples, Italien
- Rekruttering
- Azienza Ospedaliera di Rilievo Nazionale Santobono Pausilipon Dipartimento di oncologia, ematologia e terapie cellulari
-
Kontakt:
- Giuseppe Menna
- Telefonnummer: +393485171510
- E-mail: giumenna56@libero.it
-
Verona, Italien
- Ikke rekrutterer endnu
- Università degli Studi di Verona Department of Engineering for Innovation Medicine
-
Kontakt:
- Anna Savoia
- Telefonnummer: +393284695593
- E-mail: Anna.savoia@univr.it
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
All patients with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Beskrivelse
Inclusion Criteria:
- Patients diagnosed with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH).
- Signed informed consent and/or assent obtained from the participant and/or their parents or legal guardians, as applicable.
Exclusion Criteria:
- Absence of signed informed consent and/or assent from the participant and/or their parents or legal guardians
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Fanconi anemia (FA)
Fanconi anemia (FA) |
|
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD)
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD) |
|
Congenital neutropenia (CN)
Congenital neutropenia (CN) |
|
Primary immune regulatory disorders (PIRD)
Primary immune regulatory disorders (PIRD) |
|
Congenital amegakaryocytic thrombocytopenia (CAMT)
Congenital amegakaryocytic thrombocytopenia (CAMT) |
|
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Early Diagnosis and Molecular Characterization of CMF and AAA
Tidsramme: Within the 24-month project period
|
To improve the early diagnosis of constitutional bone marrow failure syndromes (CMF) and acquired aplastic anemia (AAA) through the integration of clinical, laboratory, immunological, and genetic data. At least 50 newly enrolled patients will be evaluated prospectively over the first 21 months, alongside approximately 200 previously referred patients analyzed retrospectively using artificial intelligence (AI). The diagnostic work-up will include the implementation of additional tests, such as telomere length assessment by flow-FISH, serum thrombopoietin measurement, and immunophenotyping by flow cytometry. Whole-genome sequencing and functional studies will be used to identify disease-causing variants, copy number variations (CNVs), and clarify variants of uncertain significance (VUS). Early and accurate diagnosis will support appropriate targeted treatment, genetic counseling, surveillance for bone marrow failure and malignancies, and identification of suitable related donors. |
Within the 24-month project period
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Knoglemarvssvigtsforstyrrelser
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Spædbarn, Nyfødt, Sygdomme
- Hæmatologiske sygdomme
- Hudsygdomme
- Medfødte abnormiteter
- Knoglemarvssygdomme
- Anæmi, hæmolytisk
- Anæmi
- Hudsygdomme, genetisk
- Genetiske sygdomme, X-forbundet
- Hudabnormiteter
- Myelodysplastiske syndromer
- DNA-reparation-mangellidelser
- Anæmi, hypoplastisk, medfødt
- Anæmi, aplastisk
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Hud- og bindevævssygdomme
- Hemiske og lymfatiske sygdomme
- Medfødte knoglemarvssvigtsyndromer
- Hæmoglobinuri, Paroxysmal
- Fanconi Anæmi
- Dyseratosis Congenita
- Medfødt amegakaryocytisk thrombocytopeni
- Neutropeni, svær medfødt, autosomal recessiv 3
Andre undersøgelses-id-numre
- PNRR-MR1-2023-12377081 (13958)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .